0.2556  -0.019 (-7.05%)		10-14 16:00
Open: 0.272 High: 0.272 Volume: 960,638		Pre. Close: 0.275 Low: 0.2503 Market Cap: 23(M)

Short term
Mid term
Targets	6-month :	0.4	1-year :	0.46
Resists	First :	0.34	Second :	0.4
Pivot price	0.31
Supports	First :	0.25	Second :	0.2
MAs	MA(5) :	0.28	MA(20) :	0.32
	MA(100) :	0.73	MA(250) :	1.45
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	7.2	D(3) :	8.4
RSI	RSI(14): 26.9
52-week	High :	3.61	Low :	0.25

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CNTX ] has closed below the lower bollinger band by 4.2%. Bollinger Bands are 82% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 70 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.27 - 0.27	0.27 - 0.28
Low:	0.25 - 0.25	0.25 - 0.25
Close:	0.25 - 0.26	0.26 - 0.26

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Wed, 12 Aug 2026
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan

Thu, 06 Aug 2026
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga

Wed, 05 Aug 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - GlobeNewswire

Fri, 31 Jul 2026
Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk - Stock Titan

Mon, 06 Jul 2026
Context Therapeutics joins Russell 2000 and 3000 indexes - Stock Titan

Sun, 05 Jul 2026
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	92 (M)
Shares Float	64 (M)
Held by Insiders	1.5 (%)
Held by Institutions	68.7 (%)
Shares Short	4,710 (K)
Shares Short P.Month	6,470 (K)

EPS	-0.48
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.4
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-45.8 %
Return on Equity (ttm)	-76.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.54
Qtrly Earnings Growth	0 %
Operating Cash Flow	-34 (M)
Levered Free Cash Flow	-32 (M)

PE Ratio	-0.54
PEG Ratio	0
Price to Book value	0.62
Price to Sales	0
Price to Cash Flow	-0.7

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.